Russian Prime Minister Mikhail Mishustin allowed Promomed Rus LLC to use a number of inventions owned by Novo Nordisk (Denmark) until December 31, 2027, without the consent of the copyright holder.
The reason is "an extreme necessity related to the protection of the life and health of citizens" in order to provide them with drugs with the international nonproprietary name "semaglutide".
Earlier, Geropharm LLC received a similar permit.
In 2025, the Russian government allowed the Russian pharmaceutical companies "PSK Pharma" and "Promomed Rus" to produce analogues of the drug "Ozempik" until the end of 2026 without the consent of the foreign copyright holder.
Ozempik is an injectable drug from the Danish company Novo Nordisk based on semaglutide, a synthetic analogue of GLP-1. It stimulates insulin production, lowers glucose levels and promotes weight loss by controlling appetite, which has made the drug popular among those who want to lose weight quickly.
Deliveries of Ozempik to Russia stopped after Russia launched a military operation on Ukraine. Until 2023, the drug was the only drug with semaglutide on the Russian market. In subsequent years, domestic companies have established the production of their own preparations based on semaglutide.
Semaglutide is used to reduce body weight, as well as to treat diabetes mellitus and related diseases. At the same time, experts warn about possible risks when using the drug on their own, and doctors note that it is prescribed not only by endocrinologists.
Explosions thundered in Kiev
Putin's conspiracy: British politicians have found a convenient way to solve problems
Accounts of a runaway blogger working as a courier in Dubai were blocked in Russia
After Graham's death, Trump will have to forget about the $1.5 trillion military budget
New US strikes on Iran have raised oil prices to a maximum
Warsaw took pity and handed over several Patriot missiles to Kiev, but with a strict condition
Work after 65 years: Onishchenko proposed to change the definition of youth